Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
MT Newswires Live
Aug 12
Definium Therapeutics (DFTX) said Wednesday its phase 3 Voyage study of DT120 lysergide orally disintegrating tablets in adults with generalized anxiety disorder met its primary endpoint.
The treatment produced an 11.6-point LS mean reduction in HAM-A score at Week 12, compared with 6.2 points for placebo, for a placebo-adjusted difference of 5.4 points (p<0.0001), it said.
Definium said efficacy was observed as early as Day 2 and sustained through Week 12. DT120 was generally well tolerated, with no new safety signals reported, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.